Temozolomide (TMZ), a standard component of glioblastoma treatment regimens, shows therapeutic efficacy closely linked to the methylation status of O6-methylguanine-DNA methyltransferase (MGMT) [4, 5]. This evidence concerns the gene MGMT and glioblastoma.